Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3– TransCon CNP ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

We are proud to have recently announced, approximately just six months after starting this program, achievement of the first milestone under our collaboration, having delivered AI De Novo antibody ...

Over this period, the proportion of unemployed adults rose to 4.3 per cent, up from 4 per cent in the previous period. At the ...

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Novo’s American depositary receipts rose 2.4% to $109.77 in Monday trading, but are still down 15% over the past three months ...

Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its ...